Qin, T. (2025). A multi-center, single-arm, phase II study of pemigatinib combined with immune checkpoint inhibitor in FGFR1/2/3 alteration advanced solid tumor.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps2692